Colchicine in the treatment of the cutaneous manifestations of Behcet's disease

Taniguchí, Shinkichi; Ozaki, Motoaki; Horio, Takeshi

doi:10.1111/j.1365-2133.1981.tb01713.x

Cited by 87 publications

(17 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The daily experiences and the general feelings of experts are that colchicine is of some use in BD, mainly for mucocutaneous lesions [1][2][3][4][5][6][7][8][12][13][14]. While it is rare to observe complete remission with colchicine, lesions usually become less awkward, exhibiting shorter healing times and longer remission periods.…”

Section: Discussionmentioning

confidence: 99%

“…Case reports soon confirmed the efficacy of colchicine treatment [3][4][5][6][7][8]. It was used to treat lesions caused by the disease, and resulted in some improvement.…”

Section: Introductionmentioning

confidence: 94%

“…It was used to treat lesions caused by the disease, and resulted in some improvement. However, all of the case reports focused on a few patients, with the largest studying five cases [5]. On the other hand, a double-blind controlled study [9] of 35 patients indicated that colchicine treatment was ineffective, except for erythema nodosum and arthralgia.…”

Section: Introductionmentioning

confidence: 98%

See 2 more Smart Citations

Colchicine versus placebo in Behçet’s disease: randomized, double-blind, controlled crossover trial

et al. 2009

View full text Add to dashboard Cite

The effect of colchicine was evaluated in a large cohort of Behçet's disease (BD) patients and compared to placebo. In a randomized, double-blind, controlled crossover trial, 169 patients without major organ involvement were selected consecutively. They fulfilled the International Criteria for Behçet's Disease. Patients were randomly assigned to colchicine or placebo. At 4 months, they were swapped over (colchicine to placebo, placebo to colchicine) for another 4 months. The primary outcome was the overall disease activity index, the IBDDAM. The secondary outcome was the responses of the individual symptoms. A Student's paired t test was used to evaluate results within each group, and an ANOVA to check for differences between colchicine and placebo. Analysis was performed using the "intention to treat" method. For placebo, IBDDAM worsened from 3.17 to 3.63 (t = 1.750, P = 0.08). For colchicine, IBDDAM improved from 3.35 to 2.75 (t = 4.143, P < 0.0001). Oral aphthosis, genital aphthosis, pseudofolliculitis, and erythema nodosum improved significantly with colchicine but not with placebo. According to the ANOVA, the difference in IBDDAM between colchicine and placebo was highly significant (F = 14.674, P = 0.00016). The difference between the results for males and females was not significant (F = 0.181, P = 0.67). In conclusion, colchicine, but not placebo, significantly improved the overall disease activity index. The difference between the results for colchicine and placebo was also statistically significant.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Case reports soon confirmed the efficacy of colchicine treatment [3][4][5][6][7][8]. It was used to treat lesions caused by the disease, and resulted in some improvement.…”

Section: Introductionmentioning

confidence: 94%

Section: Introductionmentioning

confidence: 98%

See 1 more Smart Citation

Colchicine versus placebo in Behçet’s disease: randomized, double-blind, controlled crossover trial

et al. 2009

View full text Add to dashboard Cite

show abstract

“…C'est en 1979 que Mascaro et al [11] si gnalent l'efficacité de la thalidomide dans l'aphtose: le produit a été utilisé avec succès par Colasson et al [5] à la dose de 100 mg par jour chez une patiente atteinte d'une aphtose bipolaire, par Kuffer et Puissant [ 10], et par Sa vlan et Saltik [ 16] chez 22 pa tients atteints de syndrome de Behçet: les si gnes cutanés et muqueux disparaissent avec 200 mg par jour du produit ; cependant les si gnes oculaires persistent [ 16], Quant à la col chicine, son efficacité dans l'aphtose a pu être étayée par plusieurs travaux récents [7][8][9][12][13][14][15]. Deux études en double aveugle [1,17] ne permettent cependant pas de conclure à son efficacité réelle, mais peutêtre les doses quotidiennes administrées (0,5-1 mg), inférieures à celles que nous avons nous-mêmes utilisées, étaient-elles in suffisantes.…”

Section: Discussionunclassified

Traitement de l’aphtose par la thalidomide et la colchicine

1984

View full text Add to dashboard Cite

Thalidomide alone (200–300 mg daily) or associated with colchicine (2–3 mg daily) was given orally to 25 patients with aphthosis: 8 patients with recurrent oral aphthae; 4 patients with recurrent mucocutaneous aphthosis, without visceral involvement, and 13 patients with Behçet’s disease (Touraine’s aphthosis). A major improvement was noted in all groups, with a rapid healing of mucous lesions and a rapid reduction of pain and burning as compared to prior spontaneous regressions. No new outbreaks were noted at a dose of 50–100 mg thalidomide and 1 mg colchicine daily. Under oral administration of the drugs, thrombophlebitis was noted in 1 case (third group) only. In the other patients with Behçet’s disease, skin aphthae, ocular symptoms, arthritis, superficial nodular phlebitis quickly disappeared with treatment. The efficiency of the drugs is only temporary, since new lesions usually appeared a few weeks after the end of treatment. Due to the relatively small number of cases studied in each group, no conclusions can be drawn concerning the efficiency of thalidomide alone compared to the association of the two drugs. However, this open trial does support the usefulness of thalidomide, or thalidomide and colchicine, in recurrent mucocutaneous aphthae, aphthosis and Behçet’s disease.

show abstract

“…Colchicine, a potent inhibitor of tubule polymerization, has been used for centuries to treat inflammatory disorders such as gout, and more recently Familial Mediterranean Fever [85], Behcet’s Disease [86], and pericarditis [87]. Colchicine is a tricyclic alkaloid derived from the flowering plant Colchicum autumnale [88], whose mechanism of action is to bind tubulin in a poorly reversible manner.…”

Section: Evaluation Of Hypothesismentioning

confidence: 99%

Colchicine to decrease NLRP3-activated inflammation and improve obesity-related metabolic dysregulation

et al. 2016

View full text Add to dashboard Cite

Obesity is a major risk-factor for the development of insulin resistance, type 2 diabetes, and cardiovascular disease. Circulating molecules associated with obesity, such as saturated fatty acids and cholesterol crystals, stimulate the innate immune system to incite a chronic inflammatory state. Studies in mouse models suggest that suppressing the obesity-induced chronic inflammatory state may prevent or reverse obesity-associated metabolic dysregulation. Human studies, however, have been far less positive, possibly because targeted interventions were too far downstream of the inciting inflammatory events. Recently, it has been shown that, within adipose tissue macrophages, assembly of a multi-protein member of the innate immune system, the NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome, is essential for the induction of this inflammatory state. Microtubules enable the necessary spatial arrangement of the components of the NLRP3 inflammasome in the cell, leading to its activation and propagation of the inflammatory cascade. Colchicine, a medication classically used for gout, mediates its anti-inflammatory effect by inhibiting tubulin polymerization, and has been shown to attenuate macrophage NLRP3 inflammasome arrangement and activation in vitro and in vivo. Given these findings, we hypothesize that, in at-risk individuals (those with obesity-induced inflammation and metabolic dysregulation), long-term colchicine use will lead to suppression of inflammation and thus cause improvements in insulin sensitivity and other obesity-related metabolic impairments.

show abstract

Colchicine in the treatment of the cutaneous manifestations of Behcet's disease

Cited by 87 publications

References 8 publications

Colchicine versus placebo in Behçet’s disease: randomized, double-blind, controlled crossover trial

Colchicine versus placebo in Behçet’s disease: randomized, double-blind, controlled crossover trial

Traitement de l’aphtose par la thalidomide et la colchicine

Colchicine to decrease NLRP3-activated inflammation and improve obesity-related metabolic dysregulation

Contact Info

Product

Resources

About